The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants

  • A.D. B
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


As the risk factors for thrombosis are becoming better understood, so is the need for anticoagulation. The inherent difficulties with warfarin are such that a low-molecular-weight heparin (LMWH) is often the key therapeutic. However, there are several different species of LMWH available to the practitioner, which leads to the need for an objective guide. New agents are coming onto the marketplace, and these may supersede both warfarin and the heparins. The current report will review the biochemistry and pharmacology of different LWMHs and identify which are more suitable for the different presentations of venous thromboembolism. It will conclude with a brief synopsis of new agents which may supersede warfarin and heparin. © 2009 Blann and Khoo, publisher and licensee Dove Medical Press Ltd.

Author-supplied keywords

  • *deep vein thrombosis/dt [Drug Therapy]
  • *deep vein thrombosis/pc [Prevention]
  • *low molecular weight heparin/ad [Drug Administrat
  • *low molecular weight heparin/ae [Adverse Drug Rea
  • *low molecular weight heparin/cm [Drug Comparison]
  • *low molecular weight heparin/dt [Drug Therapy]
  • *low molecular weight heparin/iv [Intravenous Drug
  • *low molecular weight heparin/pd [Pharmacology]
  • *low molecular weight heparin/pk [Pharmacokinetics
  • *low molecular weight heparin/sc [Subcutaneous Dru
  • *venous thromboembolism/dt [Drug Therapy]
  • *venous thromboembolism/pc [Prevention]
  • acetylsalicylic acid/ae [Adverse Drug Reaction]
  • acetylsalicylic acid/cb [Drug Combination]
  • alopecia/si [Side Effect]
  • anticoagulant agent
  • anticoagulant therapy
  • apixaban/ae [Adverse Drug Reaction]
  • apixaban/cm [Drug Comparison]
  • apixaban/cr [Drug Concentration]
  • apixaban/ct [Clinical Trial]
  • apixaban/dt [Drug Therapy]
  • apixaban/pk [Pharmacokinetics]
  • bemiparin/dt [Drug Therapy]
  • bemiparin/sc [Subcutaneous Drug Administration]
  • betrixaban/cm [Drug Comparison]
  • betrixaban/ct [Clinical Trial]
  • betrixaban/dt [Drug Therapy]
  • betrixaban/pd [Pharmacology]
  • betrixaban/pk [Pharmacokinetics]
  • betrixaban/po [Oral Drug Administration]
  • bleeding/si [Side Effect]
  • certoparin
  • clinical trial
  • continuous infusion
  • dabigatran etexilate/ae [Adverse Drug Reaction]
  • dabigatran etexilate/cb [Drug Combination]
  • dabigatran etexilate/cm [Drug Comparison]
  • dabigatran etexilate/ct [Clinical Trial]
  • dabigatran etexilate/do [Drug Dose]
  • dabigatran etexilate/dt [Drug Therapy]
  • dabigatran etexilate/it [Drug Interaction]
  • dabigatran etexilate/pk [Pharmacokinetics]
  • dalteparin/dt [Drug Therapy]
  • dalteparin/sc [Subcutaneous Drug Administration]
  • deep vein thrombosis/dt [Drug Therapy]
  • dose response
  • drug absorption
  • drug activity
  • drug antagonism
  • drug binding
  • drug bioavailability
  • drug blood level
  • drug clearance
  • drug contraindication
  • drug distribution
  • drug dose comparison
  • drug dose escalation
  • drug efficacy
  • drug elimination
  • drug excretion
  • drug half life
  • drug indication
  • drug intermittent therapy
  • drug mechanism
  • drug megadose
  • drug metabolism
  • drug safety
  • drug tolerability
  • embolism/co [Complication]
  • embolism/dt [Drug Therapy]
  • embolism/pc [Prevention]
  • enoxaparin/ae [Adverse Drug Reaction]
  • enoxaparin/cm [Drug Comparison]
  • enoxaparin/dt [Drug Therapy]
  • enoxaparin/sc [Subcutaneous Drug Administration]
  • fondaparinux/dt [Drug Therapy]
  • fondaparinux/pk [Pharmacokinetics]
  • fondaparinux/sc [Subcutaneous Drug Administration]
  • fracture/si [Side Effect]
  • heart atrium fibrillation
  • heparin induced thrombocytopenia/si [Side Effect]
  • heparin/ad [Drug Administration]
  • heparin/ae [Adverse Drug Reaction]
  • heparin/cm [Drug Comparison]
  • heparin/dt [Drug Therapy]
  • heparin/iv [Intravenous Drug Administration]
  • heparin/pd [Pharmacology]
  • heparin/pk [Pharmacokinetics]
  • heparin/sc [Subcutaneous Drug Administration]
  • high risk patient
  • human
  • hyperkalemia/si [Side Effect]
  • hypersensitivity/si [Side Effect]
  • hypoaldosteronism/si [Side Effect]
  • injection site necrosis/si [Side Effect]
  • liver toxicity/si [Side Effect]
  • low drug dose
  • lung embolism/dt [Drug Therapy]
  • monotherapy
  • nadroparin
  • osteopenia/si [Side Effect]
  • osteoporosis/si [Side Effect]
  • practice guideline
  • priapism/si [Side Effect]
  • proton pump inhibitor/it [Drug Interaction]
  • recommended drug dose
  • review
  • risk factor
  • rivaroxaban/ae [Adverse Drug Reaction]
  • rivaroxaban/cm [Drug Comparison]
  • rivaroxaban/ct [Clinical Trial]
  • rivaroxaban/do [Drug Dose]
  • rivaroxaban/dt [Drug Therapy]
  • rivaroxaban/pd [Pharmacology]
  • rivaroxaban/pk [Pharmacokinetics]
  • rivaroxaban/po [Oral Drug Administration]
  • side effect/si [Side Effect]
  • skin necrosis/si [Side Effect]
  • stroke/dt [Drug Therapy]
  • stroke/pc [Prevention]
  • thrombin inhibitor/cm [Drug Comparison]
  • thrombin inhibitor/ct [Clinical Trial]
  • thrombin inhibitor/dt [Drug Therapy]
  • thrombin inhibitor/pd [Pharmacology]
  • thrombin inhibitor/pk [Pharmacokinetics]
  • thrombin inhibitor/po [Oral Drug Administration]
  • thrombosis prevention
  • tinzaparin/dt [Drug Therapy]
  • tinzaparin/sc [Subcutaneous Drug Administration]
  • treatment duration
  • treatment response
  • venous thromboembolism/dt [Drug Therapy]
  • warfarin/ae [Adverse Drug Reaction]
  • warfarin/cb [Drug Combination]
  • warfarin/cm [Drug Comparison]
  • warfarin/dt [Drug Therapy] XT - alopecia / side e

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Blann A.D.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free